The Science of Prevention: Novel Strategies for and New Insights Into
Central Nervous System Prophylaxis in Patients With Cancer
Guest Editors: Michael Glantz, MD and Lawrence Recht, MD
Volume 36, Supplement 2 (August 2009)

Full Text Articles Now Available:

The Science of Prevention: Novel Strategies for and New Insights Into Central Nervous System Prophylaxis in Patients With Cancer
Michael Glantz and Lawrence Recht

Central Nervous System Disease in Hematologic Malignancies: Historical Perspective and Practical Applications
Ching-Hon Pui and Eckhard Thiel

Understanding the Origins of Gliomas and Developing Novel Therapies: Cerebrospinal Fluid and Subventricular Zone Interplay
Michael Glantz, Santosh Kesari, Lawrence Recht, Gudrun Fleischhack, and Alexis Van Horn

Should Intra-cerebrospinal Fluid Prophylaxis Be Part of Initial Therapy for Patients With Non-Hodgkin Lymphoma: What We Know, and How We Can Find Out More
Ulrich Herrlinger, Michael Glantz, Uwe Schlegel, Christian Gisselbrecht, and Franco Cavalli

Diagnostic Tools for Neoplastic Meningitis: Detecting Disease, Identifying Patient Risk, and Determining Benefit of Treatment
Marc C. Chamberlain, Michael Glantz, Morris D. Groves, and Wyndham H. Wilson

Treatment Modalities for Leptomeningeal Metastases
William R. Shapiro, Conrad E. Johanson, and Willem Boogerd

The Role of Intra-cerebrospinal Fluid Treatment and Prophylaxis in Patients With Solid Tumors
Riccardo Soffietti, Wallace Akerley, Randy L. Jensen, Joachim Bischoff, and Anne Constanze Regierer

Statistical and Trial Design Considerations in Central Nervous System Prophylaxis Studies
Jennifer A. Smith and Michael Glantz

VIDEO PRESENTATION
INTRODUCTION AND FAQs




INTRODUCTION

FAQ #1.
Neoplastic meningitis is rare in my experience, how commonly and in whom does it occur?

FAQ #2.
How does neoplastic meningitis present and how is it diagnosed?

FAQ #3.
Aren’t most patients with neoplastic meningitis too sick to treat for their disease?

FAQ #4.
Which patients, then, are most likely to benefit from treatment?

FAQ #5.
You’ve mentioned “CSF flow status” as a prognostic factor. I never examine that. Is it important?

FAQ #6.
Given the overall poor prognosis for patients once they develop neoplastic meningitis, what is the standard of care and are there any patient populations for whom prophylactic intra-CSF hemotherapy is appropriate?

FAQ #7.
Even more commonly than neoplastic meningitis, I see patients who develop brain metastases. How reliably can I predict which of these patients is at risk and are there reliable ways to prevent this nervous system complication of cancer?

FAQ #8.
My biggest concern about CSF prophylaxis of any type is the risk of causing major side effects in patients who might never have suffered a CNS metastasis. How do I weigh the risks and benefits of prophylaxis?